Glutamatergic Modulation to Facilitate Naltrexone Initiation: A randomized, controlled trial
Sponsor: |
NIDA |
Enrolling: |
Male and Female Patients |
Study Length: |
13 Weeks |
IRB Number: |
7543 |
U.S. Govt. ID: |
NCT03345173 |
Contact: |
HOPE Clinic: 646-854-9395 / hopeclinic@nyspi.columbia.edu |
This free and confidential study is recruiting healthy adults who are currently seeking treatment for opioid use (heroin, painkillers). Participants will be admitted into our inpatient unit for the first 3 to 5 days of the study. In addition to traditional medications used during detoxification, you will also receive innovative, investigative medications that may help with the transition onto Vivitrol (extended-release nalrexone). After discharge from the inpatient unit, participants will engage in twice-weekly outpatient visits for 12 weeks. These visits involve therapy sessions, meeting with a study physician, and completing measures with research assistants. Participants will receive a total of 3 Vivitrol shots throughout the study and will be referred to a community Vivitrol provider once they have completed.
This study is closed
Investigator
Elias Dakwar, MD
Are opioids (heroin or painkillers like Percocet, Oxy, etc.) a problem for you? |
Yes |
No |
Are you seeking treatment for your opioid use? |
Yes |
No |